MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Kodu・Aktsiate loetelu・Puma Biotechnology Inc

Puma Biotechnology Inc

Suletud

SektorTervishoid

6.91 2.37

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.51

Max

6.97

Põhinäitajad
By Trading Economics
Sissetulek	3M 12M
Müük	21M 76M
P/E Sektori keskmine	10.049 56.063
Kasumimarginaal	15.633
Töötajad	179
EBITDA	13M 27M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-21.75% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-46M 312M
Eelmine avamishind	4.54
Eelmine sulgemishind	6.91

Uudiste sentiment

By Acuity

50%

163 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

3.07 / 3.075 Toetus ja vastupanu

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. apr 2026, 22:56 UTC

Uudisväärsed sündmused

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1. apr 2026, 20:50 UTC

Omandamised, ülevõtmised, äriostud

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1. apr 2026, 23:55 UTC

Market Talk

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1. apr 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1. apr 2026, 23:23 UTC

Uudisväärsed sündmused

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1. apr 2026, 23:07 UTC

Tulu

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1. apr 2026, 23:02 UTC

Uudisväärsed sündmused

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1. apr 2026, 23:00 UTC

Uudisväärsed sündmused

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1. apr 2026, 23:00 UTC

Uudisväärsed sündmused

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1. apr 2026, 23:00 UTC

Uudisväärsed sündmused

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1. apr 2026, 22:39 UTC

Tulu

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1. apr 2026, 22:08 UTC

Market Talk

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1. apr 2026, 21:56 UTC

Omandamised, ülevõtmised, äriostud

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1. apr 2026, 21:31 UTC

Uudisväärsed sündmused

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1. apr 2026, 20:38 UTC

Tulu

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1. apr 2026, 20:31 UTC

Omandamised, ülevõtmised, äriostud

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1. apr 2026, 20:16 UTC

Omandamised, ülevõtmised, äriostud

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1. apr 2026, 20:16 UTC

Omandamised, ülevõtmised, äriostud

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1. apr 2026, 20:13 UTC

Omandamised, ülevõtmised, äriostud

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1. apr 2026, 20:07 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1. apr 2026, 20:07 UTC

Omandamised, ülevõtmised, äriostud

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

-21.75% langus

12 kuu keskmine prognoos

Keskmine 5 USD -21.75%

Kõrge 5 USD

Madal 5 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Puma Biotechnology Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.07 / 3.075Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

163 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.